Cargando…

T315I-mutated myeloid sarcoma

Myeloid Sarcoma (MS) is diagnosed by an extramedullary proliferation of immature granulocytic cells. Its association with chronic myeloid leukemia (CML) is rare. CML is characterized by BCR-ABL1 gene rearrangement and therapies with tyrosine kinase inhibitors (TKI) are very effective. However, TKI r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yumeng, Swoboda, David M., Grover, Aditya, Nodzon, Lisa, Zhang, Ling, Pinilla-Ibarz, Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715886/ https://www.ncbi.nlm.nih.gov/pubmed/31485411 http://dx.doi.org/10.1016/j.lrr.2019.100184

Ejemplares similares

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome‐positive leukemias with the T315I mutation
por: Nicolini, Franck E., et al.
Publicado: (2017)

P673: ASCIMINIB MANAGMENT IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH T315I MUTATION.
por: Kuzmina, Elena, et al.
Publicado: (2023)

I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition
por: Gao, Congying, et al.
Publicado: (2023)

Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia
por: Yusoff, Yuslina Mat, et al.
Publicado: (2018)

Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation
por: Wang, Le-Xun, et al.
Publicado: (2016)

Differentiation of imatinib -resistant chronic myeloid leukemia cells with BCR-ABL-T315I mutation induced by Jiyuan Oridonin A
por: Xu, Yun, et al.
Publicado: (2023)

Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case
por: Al-Achkar, Walid, et al.
Publicado: (2014)

P672: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND T315I MUTATION AFTER FAILURE OF PRIOR THERAPIES
por: Bidikian, Aram, et al.
Publicado: (2023)

A case report and case review: Chronic myeloid leukemia (CML) blast phase with myelomastocytic differentiation
por: Song, Jinming, et al.
Publicado: (2020)

Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation
por: Jiang, Liang, et al.
Publicado: (2021)

Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia
por: Wang, Huafeng, et al.
Publicado: (2022)

A case of chronic myelogenous leukemia with the T315I mutation who progressed to myeloid blast phase and was successfully treated with asciminib
por: Tomassetti, Sarah, et al.
Publicado: (2022)

Cardiovascular Adverse Events and Mitigation Strategies for Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor Therapy
por: Nodzon, Lisa, et al.
Publicado: (2022)

A single-tube allele specific-polymerase chain reaction to detect T315I resistant mutation in chronic myeloid leukemia patients
por: Wongboonma, Wanwisa, et al.
Publicado: (2011)

An interesting case of chronic myeloid leukemia (CML) with T315I mutation raising suspicion of de novo AML, a diagnostic conundrum
por: Iqbal, Phool, et al.
Publicado: (2023)

Target Inhibition of CBP Induced Cell Senescence in BCR-ABL- T315I Mutant Chronic Myeloid Leukemia
por: Yang, Ke, et al.
Publicado: (2021)

Successful treatment of T315I BCR-ABL mutated lymphoid blast phase chronic myeloid leukemia with chimeric antigen receptor T cell therapy followed by dasatinib
por: Zhang, Hao, et al.
Publicado: (2020)

Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation
por: Takahashi, Naoto, et al.
Publicado: (2012)

Validation of a Drosophila model of wild-type and T315I mutated BCR-ABL1 in chronic myeloid leukemia: an effective platform for treatment screening
por: Outa, Amani Al, et al.
Publicado: (2020)

Discovery of a small molecule targeting SET-PP2A interaction to overcome BCR-ABLT315I mutation of chronic myeloid leukemia
por: Wang, Shuzhen, et al.
Publicado: (2015)

Stabilization of MYC G-quadruplex DNA by ruthenium (II) complex overcomes imatinib resistance in chronic myeloid leukemia cells harboring T315I mutation
por: Sun, Yuening, et al.
Publicado: (2022)

HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation
por: Kim, Soo Jung, et al.
Publicado: (2014)

Characteristics and mutation analysis of Ph-positive leukemia patients with T315I mutation receiving tyrosine kinase inhibitors
por: Xu, Peipei, et al.
Publicado: (2017)

Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations
por: Sweet, Kendra, et al.
Publicado: (2014)

Biomarkers for determining the prognosis in chronic myelogenous leukemia
por: Sweet, Kendra, et al.
Publicado: (2013)

Bosutinib Therapy in Patients With Chronic Myeloid Leukemia: Practical Considerations for Management of Side Effects
por: Ault, Patricia S., et al.
Publicado: (2016)

T315I(+) tyrosine-kinase independent CML cells resistance
por: Nicolini, Franck Emmanuel, et al.
Publicado: (2017)

Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation
por: Okabe, Seiichi, et al.
Publicado: (2015)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism
por: Khateb, Mamduh, et al.
Publicado: (2012)

Health Tract No. 315: Presentiments
Publicado: (1868)

A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I Mutation
por: Nicolini, Franck-Emmanuel, et al.
Publicado: (2023)

Reviewers BJCVS 31.5
Publicado: (2016)

Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model
por: Nestvold, Janne, et al.
Publicado: (2017)

Targeting the PTP1B‐Bcr‐Abl1 interaction for the degradation of T315I mutant Bcr‐Abl1 in chronic myeloid leukemia
por: Elgehama, Ahmed, et al.
Publicado: (2022)

SAT-315 SDHC Germline Mutation Carrier with Primary Paraganglioma of the Thyroid Gland
por: Lee, Hyunju, et al.
Publicado: (2019)

Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report
por: Komeno, Yukiko, et al.
Publicado: (2017)

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
por: Jiang, Qian, et al.
Publicado: (2022)

BCR: a new target in resistance mediated by BCR/ABL-315I?
por: Haberbosch, Isabella, et al.
Publicado: (2016)

Role of ofatumumab in treatment of chronic lymphocytic leukemia
por: Veliz, Marays, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_q7dnsfe26kehf5c27cmciugsff